Biomea Fusion, Inc.
NASDAQ:BMEA
4.06 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Biomea Fusion, Inc. |
Symbool | BMEA |
Munteenheid | USD |
Prijs | 4.06 |
Beurswaarde | 147,129,122 |
Dividendpercentage | 0% |
52-weken bereik | 3.61 - 20.21 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Andrew Butler |
Website | https://biomeafusion.com |
An error occurred while fetching data.
Over Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)